A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

Summary

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.

Timeline

Start

2025-03-19

Primary completion

2025-11-10

Completion

2026-06-05

Outcome

Outcome not reported

Stopped: “The interim analysis data failed to demonstrate the intended treatment effect.”

Drugs

Indications